College of Sciences
Permanent URI for this communityhttps://hdl.handle.net/20.500.12588/256
Browse
Browsing College of Sciences by Author "Abastabar, Mahdi"
Now showing 1 - 10 of 10
- Results Per Page
- Sort Options
Item Confirmation of fifth Candida auris clade by whole genome sequencing(Taylor and Francis Group, 2022-10-18) Spruijtenburg, Bram; Badali, Hamid; Abastabar, Mahdi; Mirhendi, Hossein; Khodavaisy, Sadegh; Sharifisooraki, Joobin; Taghizadeh Armaki, Mojtaba; de Groot, Theun; Meis, Jacques F.Candida auris has emerged globally as a multidrug-resistant pathogen causing outbreaks in health care facilities. Whole genome sequencing (WGS) analysis has identified four major clades, while earlier WGS data from a single Iranian isolate suggested the existence of a potential fifth clade. Here, we confirm the existence of this fifth clade by providing WGS data of another four Iranian isolates. These clade V isolates differed less than 100 single-nucleotide polymorphisms (SNPs) between each other, while they were separated from the other clades by more than 200,000 SNPs. Two of these isolates were resistant to fluconazole and were found to harbour mutations in the TAC1b and ERG11 genes.Item First fluconazole-resistant Candida auris isolated from fungal otitis in Iran(Mazandaran University of Medical Sciences, 2021-03) Taghizadeh Armaki, Mojtaba; Mahdavi Omran, Saeid; Kiakojuri, Keivan; Khojasteh, Shaghayegh; Jafarzadeh, Jalal; Tavakoli, Mahin; Badali, Hamid; Haghani, Iman; Shokohi, Tahereh; Hedayati, Mohammad T.; Abastabar, MahdiBackground and Purpose: Candida auris, as a new characterized pathogenic yeast,has attracted remarkable attention in the recent decade due to its rapid global emergence and multidrug resistance traits. This unique species is able to cause nosocomial outbreaks and tolerate adverse conditions; however, it has been mostly misidentified by conventional methods. Case report: This report aimed to describe the first fluconazole-resistant case of C.auris otitis in an immunocompetent patient in Iran. The isolate showed minimum inhibitory concentration of ≥ 32 μg/ml for fluconazole; however, the patient was treated with topical clotrimazole and miconazole with no recurrence. Conclusion: This was the second strain of C. auris isolated from otitis in Iran which was fluconazole-resistant, unlike the first Iranian isolate.Item Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry(BMC, 2018-01-08) Aslani, Narges; Janbabaei, Ghasem; Abastabar, Mahdi; Meis, Jacques F.; Babaeian, Mahasti; Khodavaisy, Sadegh; Boekhout, Teun; Badali, HamidBackground: Opportunistic infections due to Candida species occur frequently in cancer patients because of their inherent immunosuppression. The aim of the present study was to investigate the epidemiology of yeast species from the oral cavity of patients during treatment for oncological and haematological malignancies. Methods: MALDI-TOF was performed to identify yeasts isolated from the oral cavity of 350 cancer patients. Moreover, antifungal susceptibility testing was performed in according to CLSI guidelines (M27-A3). Results: Among 162 yeasts and yeast-like fungi isolated from the oral cavity of cancer patients, Candida albicans was the most common species (50.6%), followed by Candida glabrata (24.7%), Pichia kudriavzevii (Candida krusei (9.9%)), Candida tropicalis (4.3%), Candida dubliniensis (3.7%), Kluyveromyces marxianus (Candida kefyr (3.7%)) and Candida parapsilosis (1%). In addition, uncommon yeast species i.e., Saprochaete capitata, Saccharomyces cerevisiae, Clavispora lusitaniae (C. lusitaniae) and Pichia kluyveri (C. eremophila) were recovered from oral lesions. Oral colonization by C. albicans, non-albicans Candida species and uncommon yeasts were as follow; 55%, 44% and 1%, whereas oral infection due to C. albicans was 33.3%, non-albicans Candida species 60.6%, and uncommon yeasts 6.1%. Poor oral hygiene and xerostomia were identified as independent risk factors associated with oral yeast colonization. The overall resistance to fluconazole was 11.7% (19/162). Low MIC values were observed for anidulafungin for all Candida and uncommon yeast species. Conclusions: This current study provides insight into the prevalence and susceptibility profiles of Candida species, including emerging Candida species and uncommon yeasts, isolated from the oral cavity of Iranian cancer patients. The incidence of oral candidiasis was higher amongst patients with hematological malignancies. The majority of oral infections were caused by non-albicans Candida species which were often more resistant to anti-fungal agents. Our findings suggest that anidulafungin should be used as antifungal of choice for prophylaxis in clinically high-risk patients with documented oral colonization or infection.Item In Vitro Antifungal Activity of Novel Triazole Efinaconazole and Five Comparators against Dermatophyte Isolates(American Society for Microbiology, 2018-04-26) Rezaei-Matehkolaei, Ali; Khodavaisy, Sadegh; Alshahni, Mohamad Mahdi; Tamura, Takashi; Satoh, Kazuo; Abastabar, Mahdi; Shokoohi, Gholam Reza; Ahmadi, Bahram; Kord, Mohammad; Taghipour, Simin; Makimura, Koichi; Badali, HamidThe objective of this study was to assess the in vitro activity of the novel triazole antifungal drug, efinaconazole, and five comparators (luliconazole, lanoconazole, terbinafine, itraconazole, and fluconazole) against a large collection of Trichophyton interdigitale and Trichophyton rubrum clinical isolates. The geometric mean MICs were the lowest for luliconazole (0.0005 μg/ml), followed by lanoconazole (0.002 μg/ml), efinaconazole (0.007 μg/ml), terbinafine (0.011 μg/ml), itraconazole (0.095 μg/ml), and fluconazole (12.77 μg/ml). It appears that efinaconazole, lanoconazole, and luliconazole are promising candidates for the treatment of dermatophytosis due to T. interdigitale and T. rubrum.Item In Vitro Antifungal Susceptibility Profile of Miltefosine against a Collection of Azole and Echinocandins Resistant Fusarium Strains(2022-07-04) Nosratabadi, Mohsen; Akhtari, Javad; Faeli, Leila; Haghani, Iman; Aghili, Seyed Reza; Shokohi, Tahereh; Hedayati, Mohammad Taghi; Zarrinfar, Hossein; Mohammadi, Rasoul; Najafzadeh, Mohammad Javad; Khodavaisy, Sadegh; Al-Harrasi, Ahmed; Javan-Nikkhah, Mohammad; Kachuei, Reza; Salimi, Maryam; Fattahi, Mahsa; Badali, Hamid; Al Hatmi, Abdullah M. S.; Abastabar, MahdiFusarium species are filamentous fungi that cause a variety of infections in humans. Because they are commonly resistant to many antifungal drugs currently available in clinical settings, research into alternative targets in fungal cells and therapeutic approaches is required. The antifungal activity of miltefosine and four comparators, amphotericin B, voriconazole, itraconazole, and caspofungin, were tested in vitro against a collection of susceptible and resistant clinical (n = 68) and environmental (n = 42) Fusarium isolates. Amphotericin B (0.8 µg/mL) had the lowest geometric mean (GM) MICs/MECs values followed by miltefosine (1.44 µg/mL), voriconazole (2.15 µg/mL), caspofungin (7.23 µg/mL), and itraconazole (14.19 µg/mL). Miltefosine was the most effective agent against Fusarium isolates after amphotericin B indicating that miltefosine has the potential to be studied as a novel treatment for Fusarium infections.Item Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis(American Society for Microbiology, 2018-11-26) Abastabar, Mahdi; Haghani, Iman; Shokohi, Tahereh; Hedayati, Mohammad Taghi; Aghili, Seyed Reza; Jedi, Ali; Dadashi, Sulmaz; Shabanzadeh, Shafigheh; Hosseini, Tahereh; Aslani, Narges; Meis, Jacques F.; Badali, HamidThe in vitro activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to Candida species, Aspergillus species, and dermatophytes.Item Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex(Microbiology Society, 2020-01-01) Bandalizadeh, Zainab; Shokohi, Tahereh; Badali, Hamid; Abastabar, Mahdi; Babamahmoudi, Farhang; Davoodi, Lotfolah; Mardani, Masoud; Javanian, Mostafa; Cheraghmakani, Hamed; Sepidgar, Ali Asghar; Badiee, Parisa; Khodavaisy, Sadegh; Afshari, Setareh Agha Kuchak; Ahmadikia, Kazem; Seyedmousavi, SeyedmojtabaIntroduction. Limited data regarding the epidemiology and susceptibility profiles of cryptococcosis are available in the Middle East. Aim. Our study aimed to evaluate the molecular diversity, mating types and antifungal susceptibility pattern of Cryptococcus species (n=14) isolated from 320 suspected patients with cryptococcosis. Methodology. The URA5 gene was subjected to restriction fragment length polymorphism and sequence analysis. In addition, in vitro antifungal susceptibility testing was performed by Clinical and Laboratory Standards Institute (CLSI) M27-A4 and M59 guidelines. Results. Overall, 14 (4.4 %) patients were confirmed as cryptococcosis. Based on molecular type, 85.7 and 14.3 % of the isolates were C. neoformans VN I and VN II, respectively. Phylogenetic analysis of URA5 gene sequences revealed clustering of VN I and VN II isolates into two distinct clades with a substantial difference within each molecular type. Voriconazole and 5-fluorocytosine, respectively, had the lowest (0.031 μg ml−1) and highest (8 µg ml−1) MICs. The epidemiological cutoff values (ECVs) for amphotericin B, fluconazole, voriconazole and 5-fluorocytosine encompassed ≥97 % of all 14 C. neoformans VN I species. However, according to the CLSI document M59, ECVs for itraconazole (7; 50 % of the isolates) and for posaconazole (1; 7.1 % of the isolate), were one log2 dilution higher than the wild type range. Combinations of amphotericin B with 5-fluorocytosine, amphotericin B with fluconazole and fluconazole with 5-fluorocytosine exhibited synergistic effects against 37, 31 and 12.5 % of the isolates, respectively. Conclusion. Our findings may significantly contribute to the development of management strategies for patients at a higher risk of cryptococcosis, particularly HIV-positive individuals.Item Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species(American Society for Microbiology, 2018-04-26) Abastabar, Mahdi; Moghaddam, Mohammad Vafaei; de Hoog, G. Sybren; Haghani, Iman; Aghili, Seyed Reza; Shokohi, Tahereh; Hedayati, Mohammad Taghi; Ghazvini, Roshanak Daie; Kachuei, Reza; Rezaei-Matehkolaei, Ali; Makimura, Koichi; Meis, Jacques F.; Badali, HamidA collection of clinical (n = 47) and environmental (n = 79) Fusarium isolates were tested against 10 antifungal drugs, including 2 novel imidazoles. Luliconazole and lanoconazole demonstrated very low geometric mean MIC values of 0.005 and 0.013 μg/ml, respectively, compared with 0.51 μg/ml for micafungin, 0.85 μg/ml for efinaconazole, 1.12 μg/ml for natamycin, 1.18 μg/ml for anidulafungin, 1.31 μg/ml for voriconazole, 1.35 μg/ml for caspofungin, 1.9 μg/ml for amphotericin B, and 4.08 μg/ml for itraconazole. Results show that these drugs are potential candidates for (topical) treatment of skin and nail infections due to Fusarium species.Item Potent Activities of Novel Imidazoles Lanoconazole and Luliconazole against a Collection of Azole-Resistant and -Susceptible Aspergillus fumigatus Strains(American Society for Microbiology, 2016-10-21) Abastabar, Mahdi; Rahimi, Nooshin; Meis, Jacques F.; Aslani, Narges; Khodavaisy, Sadegh; Nabili, Mojtaba; Rezaei-Matehkolaei, Ali; Makimura, Koichi; Badali, HamidA collection of azole-susceptible (n = 141) and azole-resistant (n = 27) Aspergillus fumigatus isolates was tested against seven antifungal drugs, including the new imidazoles lanoconazole and luliconazole. The luliconazole and lanoconazole MIC90 values for the azole-susceptible strains were 0.001 μg/ml and 0.008 μg/ml, and those for the azole-resistant strains were 0.016 μg/ml and 0.032 μg/ml.Item Potential Inhibitory Effect of Miltefosine against Terbinafine-Resistant Trichophyton indotineae(MDPI, 2023-04-17) Haghani, Iman; Akhtari, Javad; Yahyazadeh, Zahra; Espahbodi, Amirreza; Kermani, Firoozeh; Javidnia, Javad; Hedayati, Mohammad Taghi; Shokohi, Tahereh; Badali, Hamid; Rezaei-Matehkolaei, Ali; Aghili, Seyed Reza; Al-Rawahi, Ahmed; Al-Harrasi, Ahmed; Abastabar, Mahdi; Al-Hatmi, Abdullah M. S.Several prolonged and significant outbreaks of dermatophytosis caused by Trichophyton indotineae, a new emerging terbinafine-resistant species, have been ongoing in India in recent years, and have since spread to various countries outside Asia. Miltefosine, an alkylphosphocholine, is the most recently approved drug for the treatment of both visceral and cutaneous leishmaniasis. Miltefosine in vitro activity against terbinafine-resistant and susceptible T. mentagrophytes/T. interdigitale species complex, including T. indotineae, is limited. The current study aimed to assess miltefosine’s in vitro activity against dermatophyte isolates, which are the most common causes of dermatophytosis. Miltefosine, terbinafine, butenafine, tolnaftate, and itraconazole susceptibility testing was performed using Clinical and Laboratory Standards Institute broth microdilution methods (CLSI M38-A3) against 40 terbinafine-resistant T. indotineae isolates and 40 terbinafine-susceptible T. mentagrophytes/T. interdigitale species complex isolates. Miltefosine had MIC ranges of 0.063–0.5 µg/mL and 0.125–0.25 µg/mL against both terbinafine-resistant and susceptible isolates. In terbinafine-resistant isolates, the MIC50 and MIC90 were 0.125 µg/mL and 0.25 µg/mL, respectively, and 0.25 µg/mL in susceptible isolates. Miltefosine had statistically significant differences in MIC results when compared to other antifungal agents (p-value 0.05) in terbinafine-resistant strains. Accordingly, the findings suggest that miltefosine has a potential activity for treating infections caused by terbinafine-resistant T. indotineae. However, further studies are needed to determine how well this in vitro activity translates into in vivo efficacy.